Advanced

Increased Levels of Copeptin, a Surrogate Marker of Arginine Vasopressin, Are Associated with an Increased Risk of Chronic Kidney Disease in a General Population

Tasevska, Irina LU ; Enhörning, Sofia LU ; Christensson, Anders LU ; Persson, Margaretha LU ; Nilsson, Peter M. LU and Melander, Olle LU (2016) In American Journal of Nephrology p.22-28
Abstract

Background: Our aim was to test if plasma copeptin, a stable surrogate marker of arginine vasopressin, predicts decline of glomerular filtration rate (GFR) and risk of chronic kidney disease (CKD). Methods: We measured copeptin and renal function at the Malmö Diet and Cancer Cardiovascular Cohort baseline exam and reassessed renal function after a follow-up time of 16.6 ± 1.5 years (n = 3,186). Furthermore, we defined CKD based on an estimated GFR (eGFR) calculated by the Modification of Diet in Renal Disease (MDRD) MDRD), MDRD) and MDRD) ml/min/1.73 m2. Results: After multivariate adjustment (gender, age, baseline eGFR, smoking status, systolic blood pressure, antihypertensive treatment and follow-up time), copeptin... (More)

Background: Our aim was to test if plasma copeptin, a stable surrogate marker of arginine vasopressin, predicts decline of glomerular filtration rate (GFR) and risk of chronic kidney disease (CKD). Methods: We measured copeptin and renal function at the Malmö Diet and Cancer Cardiovascular Cohort baseline exam and reassessed renal function after a follow-up time of 16.6 ± 1.5 years (n = 3,186). Furthermore, we defined CKD based on an estimated GFR (eGFR) calculated by the Modification of Diet in Renal Disease (MDRD) MDRD), MDRD) and MDRD) ml/min/1.73 m2. Results: After multivariate adjustment (gender, age, baseline eGFR, smoking status, systolic blood pressure, antihypertensive treatment and follow-up time), copeptin (beta-coefficient per 1 SD increment of copeptin) was independently associated with significantly greater annual decline of eGFR (ml/min/1.73 m2) according to the MDRD formula (OR 0.057, 95% CI 0.022-0.093; p = 0.001) as well as according to the CKD Epidemiology Collaboration (CKD-EPI) formula (OR 0.050, 95% CI 0.022-0.077; p <0.001). Each SD increment of copeptin independently predicted incident CKD_60MDRD (OR 1.19, 95% CI 1.04-1.36; p = 0.010), CKD_45MDRD (OR 1.33, 95% CI 1.04-1.71; p = 0.026) and CKD_30MDRD (OR 3.69, 95% CI 1.41-9.66; p = 0.008). The relationship between copeptin and CKD defined by CKD-EPI gave similar results. Conclusion: Our data suggest that increased levels of copeptin independently predict decline in eGFR and greater risk of new-onset CKD.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
Chronic kidney disease, Copeptin, Epidemiology, Estimated glomerular filtration rate
in
American Journal of Nephrology
pages
7 pages
publisher
Karger
external identifiers
  • Scopus:84976585191
ISSN
0250-8095
DOI
10.1159/000447522
language
English
LU publication?
yes
id
637a44c5-9854-48db-aba4-2bd862c8c97e
date added to LUP
2016-07-18 09:47:50
date last changed
2016-10-13 05:11:44
@misc{637a44c5-9854-48db-aba4-2bd862c8c97e,
  abstract     = {<p>Background: Our aim was to test if plasma copeptin, a stable surrogate marker of arginine vasopressin, predicts decline of glomerular filtration rate (GFR) and risk of chronic kidney disease (CKD). Methods: We measured copeptin and renal function at the Malmö Diet and Cancer Cardiovascular Cohort baseline exam and reassessed renal function after a follow-up time of 16.6 ± 1.5 years (n = 3,186). Furthermore, we defined CKD based on an estimated GFR (eGFR) calculated by the Modification of Diet in Renal Disease (MDRD) MDRD), MDRD) and MDRD) ml/min/1.73 m<sup>2</sup>. Results: After multivariate adjustment (gender, age, baseline eGFR, smoking status, systolic blood pressure, antihypertensive treatment and follow-up time), copeptin (beta-coefficient per 1 SD increment of copeptin) was independently associated with significantly greater annual decline of eGFR (ml/min/1.73 m<sup>2</sup>) according to the MDRD formula (OR 0.057, 95% CI 0.022-0.093; p = 0.001) as well as according to the CKD Epidemiology Collaboration (CKD-EPI) formula (OR 0.050, 95% CI 0.022-0.077; p &lt;0.001). Each SD increment of copeptin independently predicted incident CKD_60<sub>MDRD</sub> (OR 1.19, 95% CI 1.04-1.36; p = 0.010), CKD_45<sub>MDRD</sub> (OR 1.33, 95% CI 1.04-1.71; p = 0.026) and CKD_30<sub>MDRD</sub> (OR 3.69, 95% CI 1.41-9.66; p = 0.008). The relationship between copeptin and CKD defined by CKD-EPI gave similar results. Conclusion: Our data suggest that increased levels of copeptin independently predict decline in eGFR and greater risk of new-onset CKD.</p>},
  author       = {Tasevska, Irina and Enhörning, Sofia and Christensson, Anders and Persson, Margaretha and Nilsson, Peter M. and Melander, Olle},
  issn         = {0250-8095},
  keyword      = {Chronic kidney disease,Copeptin,Epidemiology,Estimated glomerular filtration rate},
  language     = {eng},
  month        = {06},
  pages        = {22--28},
  publisher    = {ARRAY(0xaf56028)},
  series       = {American Journal of Nephrology},
  title        = {Increased Levels of Copeptin, a Surrogate Marker of Arginine Vasopressin, Are Associated with an Increased Risk of Chronic Kidney Disease in a General Population},
  url          = {http://dx.doi.org/10.1159/000447522},
  year         = {2016},
}